Borthwick AD - Search Results

1

2,5-diketopiperazines in food and beverages: Taste and bioactivity.

Borthwick AD, Da Costa NC. Borthwick AD, et al. Crit Rev Food Sci Nutr. 2017 Mar 4;57(4):718-742. doi: 10.1080/10408398.2014.911142. Crit Rev Food Sci Nutr. 2017. PMID: 25629623 Review.

2

2,5-Diketopiperazines: synthesis, reactions, medicinal chemistry, and bioactive natural products.

Borthwick AD. Borthwick AD. Chem Rev. 2012 Jul 11;112(7):3641-716. doi: 10.1021/cr200398y. Epub 2012 May 11. Chem Rev. 2012. PMID: 22575049 Review. No abstract available.

3

Oral oxytocin antagonists.

Borthwick AD. Borthwick AD. J Med Chem. 2010 Sep 23;53(18):6525-38. doi: 10.1021/jm901812z. J Med Chem. 2010. PMID: 20550119 No abstract available.

4

Fluparoxan: A Comprehensive Review of its Discovery, Adrenergic and CNS Activity and Treatment of Cognitive Dysfunction in Central Neurodegenerative Diseases.

Borthwick AD. Borthwick AD. Mini Rev Med Chem. 2017;17(7):572-582. doi: 10.2174/1389557516666160321115041. Mini Rev Med Chem. 2017. PMID: 26996616 Review.

5

The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor.

Borthwick AD, Liddle J. Borthwick AD, et al. Med Res Rev. 2011 Jul;31(4):576-604. doi: 10.1002/med.20193. Epub 2009 Dec 21. Med Res Rev. 2011. PMID: 20027670

6

Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.

Borthwick AD, Liddle J, Davies DE, Exall AM, Hamlett C, Hickey DM, Mason AM, Smith IE, Nerozzi F, Peace S, Pollard D, Sollis SL, Allen MJ, Woollard PM, Pullen MA, Westfall TD, Stanislaus DJ. Borthwick AD, et al. J Med Chem. 2012 Jan 26;55(2):783-96. doi: 10.1021/jm201287w. Epub 2012 Jan 12. J Med Chem. 2012. PMID: 22239250

7

2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.

Borthwick AD, Davies DE, Exall AM, Livermore DG, Sollis SL, Nerozzi F, Allen MJ, Perren M, Shabbir SS, Woollard PM, Wyatt PG. Borthwick AD, et al. J Med Chem. 2005 Nov 3;48(22):6956-69. doi: 10.1021/jm050557v. J Med Chem. 2005. PMID: 16250654

8

Design of translactam HCMV protease inhibitors as potent antivirals.

Borthwick AD. Borthwick AD. Med Res Rev. 2005 Jul;25(4):427-52. doi: 10.1002/med.20030. Med Res Rev. 2005. PMID: 15789440 Review.

9

2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.

Borthwick AD, Davies DE, Exall AM, Hatley RJ, Hughes JA, Irving WR, Livermore DG, Sollis SL, Nerozzi F, Valko KL, Allen MJ, Perren M, Shabbir SS, Woollard PM, Price MA. Borthwick AD, et al. J Med Chem. 2006 Jul 13;49(14):4159-70. doi: 10.1021/jm060073e. J Med Chem. 2006. PMID: 16821776

10

Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.

Borthwick AD, Davies DE, Ertl PF, Exall AM, Haley TM, Hart GJ, Jackson DL, Parry NR, Patikis A, Trivedi N, Weingarten GG, Woolven JM. Borthwick AD, et al. J Med Chem. 2003 Oct 9;46(21):4428-49. doi: 10.1021/jm030810w. J Med Chem. 2003. PMID: 14521407

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page